
Cardiff Oncology Inc (NASDAQ:CRDF) shares are trading lower after the company announced data from its lead clinical program evaluating onvansertib in combination with standard-of-care FOLFIRI/bevacizumab.
"As we have increased the number of patients evaluated and the duration of follow-up, our Phase 1b/2 trial has consistently generated data suggesting that onvansertib provides meaningful clinical benefits when added to SOC," said Katherine L. Ruffner, M.D., chief medical officer of Cardiff Oncology.